alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
INITIAL REVIEW ENGINEERING REPORT s

PMN: 15-0188 

Post-Focus Draft Revision 1 4/2/2015

PV (kg/yr): 

ENGINEER: Macek \ DDB 

 

SUBMITTER: Allnex USA Inc. 

MSDS: Yes Label: No

Gen Eqpt: Where this material is not used in a closed system, good 

enclosure and local exhaust ventilation should be provided to control

exposure when spraying or curing at elevated temperatures. // Wear 

eye/face protection such as chemical splash proof goggles or face 

shield. // Wear impermeable gloves and suitable protective clothing. 

Gloves for short-term exposure: Laminated multilayer gloves and 

nitrile rubber. Not suitable gloves: Latex

Respirator: For operations where inhalation exposure can occur use an 

approved respirator. Full face mask with organic vapor cartridge, Type 

A filter (BP > 65 deg C).

Health Effects: None known.

TLV/PEL:

None established. 
 

 

 

 

 

27/2015):

Analogs:

Related Cases and Misc SAT Info: 

Migration to groundwater: Negligible 

PBT rating: P3B1T1 

Health: 1-2 Dermal, Drinking Water, Inhalation 

Eco: 3 Water (All releases to water with a CC = 7 ppb) 
OCCUPATIONAL EXPOSURE RATING: 2C

NOTES & KEY ASSUMPTIONS: 

Generated by the 09/30/2013 version of ChemSTEER. 

 

POLLUTION PREVENTION CONSIDERATIONS:

No Pollution Prevention information provided by the submitter.

EXPOSURE-BASED REVIEW: No 
INITIAL REVIEW ENGINEERING REPORT

PMN: 15-0188 

Processing: 

unknown site(s) 

Number of Sites/ Location: 1 

Days/yr: 30

ENVIRONMENTAL RELEASES ESTIMATE SUMMARY

IRER Note: The daily releases listed for any source below may coincide 

with daily releases from the other sources to the same medium.


INITIAL REVIEW ENGINEERING REPORT

PMN: 15-0188 

unknown site(s) 

Number of Sites/ Location: 5 

Days/yr: 250

ENVIRONMENTAL RELEASES ESTIMATE SUMMARY

IRER Note: The daily releases listed for any source below may coincide 

with daily releases from the other sources to the same medium.
Water or Incineration or Landfill

High End: 2.2E+0 kg/site-day over 19 days/yr from 5 sites

or 4.2E+1 kg/site-yr from 5 sites or 2.1E+2 kg/yr-all sites

Water or Incineration or Landfill

Output 1: 1.1E-1 kg/site-day over 250 days/yr from 5 sites

or 2.8E+1 kg/site-yr from 5 sites or 1.4E+2 kg/yr-all sites

Incineration or Landfill

Conservative: 1.1E-1 kg/site-day over 250 days/yr from 5 sites

or 2.8E+1 kg/site-yr from 5 sites or 1.4E+2 kg/yr-all sites

RELEASE TOTAL

4.8E+2 kg/yr - all sites
 

 

 

 

 

 
CALL BY: 

CALL TO: 

Organization: 

Date: 

Time: 

PMN: 15-0188 

Organization: 

Phone: 

Concerning what?

CBI: No

MEMORANDUM of TELEPHONE CONVERSATION (Contains No TSCA CBI)
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.6290 Prophylaxis cup. ( a ) *Identification.* A prophylaxis cup is a device made of rubber intended to be held by a dental handpiece and used to apply polishing agents during prophylaxis (cleaning). The dental handpiece spins the rubber cup holding the polishing agent and the user applies it to the teeth to remove debris.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 872.9. If the device is not labeled or otherwise represented as sterile, it is exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[52 FR 30097, Aug. 12, 1987, as amended at 54 FR 13831, Apr. 5, 1989; 66 FR 38799, July 25, 2001]
Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of
MBIA Inc. (the Company) on Form 10-Q for the period ending September 30, 2009 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, C. Edward Chaplin, Chief Financial Officer of
the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
| | --- | ---------------------------------------------------------------------------------------------------------------------------------------------------



|                       
|-----------------------
|/s/ C. Edward Chaplin  
|C. Edward Chaplin      
|Chief Financial Officer
|November 9, 2009
<PAGE>   1

                                                                    EXHIBIT 23.2

                    [KPMG CHARTERED ACCOUNTANTS LETTERHEAD]

                        CONSENT OF INDEPENDENT AUDITORS

The Board of Directors
Pivotal Corporation
(formerly Pivotal Software Inc.)

We consent to the use of our report included herein and to the reference to our
firm under the heading "Experts" in this registration statement on Form F-1.

/s/ KPMG LLP

Chartered Accountants
Vancouver, Canada

July 28, 1999
# C_2016136EN.01004402.xml

| 18.4.2016 | EN | Official Journal of the European Union | C 136/44 |
| --- | --- | --- | --- |

18.4.2016

EN

Official Journal of the European Union

C 136/44

---

Order of the General Court of 29 February 2016 — Micula and Others v Commission

(Case T-646/14) (1)

1

(2016/C 136/61)

Language of the case: English

The President of the Fourth Chamber has ordered that the case be removed from the register.

---

(1)  OJ C 439, 8.12.2014.

1

---
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1700 Total thyroxine test system. ( a ) *Identification.* A total thyroxine test system is a device intended to measure total (free and protein bound) thyroxine (thyroid hormone) in serum and plasma. Measurements obtained by this device are used in the diagnosis and treatment of thyroid diseases.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
[52 FR 16122, May 1, 1987, as amended at 84 FR 71797, Dec. 30, 2019]
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of the Treasury

# DATES:

Written comments should be received on or before April 5, 2010 to be assured of consideration.

## Bureau of Public Debt (BPD)

*OMB Number:*                     1535-0120.                

*Type of Review:*                     Extension of a previously approved collection.                

*Title:*                     FHA New Account Request, Transition Request, and Transfer Request.                

*Form:*                     5354, 5367, PD F 5366.                

*Description:*                     Used to establish account, change information on account, and transfer ownership.                

*Respondents:*                     Individuals or Households.                

*Estimated Total Burden Hours:*                     50 hours.                

*Clearance Officer:*                     Bruce Sharpe (304) 480-8150. Bureau of the Public Debt, 200 Third Street, Parkersburg, West Virginia 26106.                

*OMB Reviewer:*                     Shagufta Ahmed (202) 395-7873, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503.                

Celina Elphage,

Treasury PRA Clearance Officer.

[FR Doc. 2010-4626 Filed 3-3-10; 8:45 am]

BILLING CODE 4810-39-P
#### § 821.60 Retention of records.

Persons required to maintain records under this part shall maintain such records for the useful life of each tracked device they manufacture or distribute. The useful life of a device is the time a device is in use or in distribution for use. For example, a record may be retired if the person maintaining the record becomes aware of the fact that the device is no longer in use, has been explanted, returned to the manufacturer, or the patient has died.
**Exhibit 31.1**

 

**CERTIFICATION**

 

I, RobinRaina, certify that:

 

1. I havereviewed this quarterly report on Form 10-Q of Ebix, Inc.;

 

2. Based on myknowledge, this report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, inlight of the circumstances under which such statements were made, notmisleading with respect to the period covered by this report;

 

3. Based on myknowledge, the financial statements, and other financial information includedin this report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, andfor, the periods presented in this report;

 

4. Theregistrant’s other certifying officer and I are responsible for establishingand maintaining disclosure controls and procedures (as defined in Exchange ActRules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

(a) Designedsuch disclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this report is being prepared;

 

(b) Evaluatedthe effectiveness of the registrant’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of thedisclosure controls and procedures, as of the end of the period covered by thisreport based on such evaluation; and

 

(c) Disclosedin this report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (theregistrant’s fourth fiscal quarter in the case of an annual report) that hasmaterially affected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and

 

5. Theregistrant’s other certifying officer and I have disclosed, based on our mostrecent evaluation of internal control over financial reporting, to theregistrant’s auditors and the audit committee of the registrant’s board ofdirectors (or persons performing the equivalent functions):

 

(a) Allsignificant deficiencies and material weaknesses in the design or operation ofinternal control over financial reporting which are reasonably likely toadversely affect the registrant’s ability to record, process, summarize andreport financial information; and

 

(b) Any fraud,whether or not material, that involves management or other employees who have asignificant role in the registrant’s internal control over financial reporting.

 

 
| Date:  | May 12, 2005            | /s/ Robin Raina |   |
|--------|-------------------------|-----------------|--------|
|   | Robin Raina             |
|   | Chief Executive Officer |

 

----
# C_2019082EN.01002401.xml

| 4.3.2019 | EN | Official Journal of the European Union | C 82/24 |
| --- | --- | --- | --- |

4.3.2019

EN

Official Journal of the European Union

C 82/24

---

Judgment of the General Court of 12 December 2018 — Biogaran v Commission

(Case T-677/14) (1)

((Competition - Agreements, decisions and concerted practices - Market for perindopril, a medicinal product intended for the treatment of cardiovascular diseases, in its originator and generic versions - Decision finding an infringement of Articles 101 TFEU and 102 TFEU - Agreements intended to delay, or even prevent, the market entry of generic versions of perindopril - Participation of a subsidiary in the infringement committed by its parent company - Imputation of the infringement - Joint and several liability - Ceiling of the fine))

(2019/C 82/26)

Language of the case: French

Parties

Applicant: Biogaran (Colombes, France) (represented by: T. Reymond, O. de Juvigny and J. Jourdan, lawyers)

Defendant: European Commission (represented initially by F. Castilla Contreras, T. Vecchi and B. Mongin, and subsequently by F. Castilla Contreras, B. Mongin and C. Vollrath, acting as Agents)

Re:

Application under Article 263 TFEU for annulment of Commission Decision C(2014) 4955 final of 9 July 2014 relating to a proceeding under Article 101 and Article 102 TFEU [Case AT.39612 — Perindopril (Servier)] in so far as it concerns the applicant and, in the alternative, for reduction of the fine imposed on the applicant by that decision.

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Biogaran to pay the costs. |
| --- | --- |

2.

Orders Biogaran to pay the costs.

---

(1)  OJ C 395, 10.11.2014.

---
---

EXHIBIT 13.B





CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with Amendment No. 1 to the Annual Report of Petaquilla Minerals Ltd. (the Company) on Form 20-F for the fiscal period ended May 31, 2009, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Bassam Moubarak, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:



| |    |  |                                                                                                                                                      
| | -- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------
| | 1. |  | The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and    
| |    |  |                                                                                                                                                      
| | 2. |  | The information contained in the Report fairly presents, in all materials respects, the financial condition and results of operations of the Company.





|                              | 
|----------------------------- | 
|/s/ Bassam Moubarak           | 
|Bassam Moubarak              
|(principal financial officer)



Dated:  November 6
  , 2009





The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.





---
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT No. 01-1203

SARA MUSSIE, Petitioner, versus U.S. IMMIGRATION & NATURALIZATION SERVICE; JOHN ASHCROFT, Attorney General, Respondents. On Petition for Review of an Order of the Board of Immigration Appeals. (A-72-415-605) Submitted: July 20, 2001 Decided: August 1, 2001 Before LUTTIG, MOTZ, and TRAXLER, Circuit Judges. Affirmed by unpublished per curiam opinion. Diane McHugh-Martinez, LAW OFFICE OF MCHUGH-MARTINEZ, Washington,D.C., for Petitioner. Stuart E. Schiffer, Acting Assistant Attorney General, Margaret J. Perry, Senior Litigation Counsel, Julia K. Doig, Office of Immigration Ligitation, UNITED STATES DEPARTMENT OF JUSTICE, Washington, D.C., for Respondent. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).2 PER CURIAM: Sara Mussie, a native and citizen of Ethiopia, petitions for review of a final order of the Board of Immigration Appeals (Board) denying her motion to reopen deportation proceedings based on a claim for protection under the United Nations Convention Against Torture and Other Cruel, Inhuman, or Degrading Treatment or Punishment.Mussie contends that the Board abused its discretion in finding that she failed to establish a prima facie case that it is more likely than not that she would suffer torture if returned to either Germany or Ethiopia. See Stewart v. INS , 181 F.3d 587, 595 (4th Cir. 1999); 8 C.F.R. § 208.16(c)(2) (2001). We have reviewed the administrative record and the Board’s decision and find no abuse of discretion in its refusal to grant the motion to reopen. See 8 C.F.R. § 208.18(b)(2)(ii). Accordingly, we affirm the Board’s denial of relief. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

AFFIRMED
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.1326 Chromium hydroxide green. ( a ) *Identity.* ( 1 ) The color additive chromium hydroxide green is principally hydrated chromic sesquioxide (Cr2O3·XH2O).
( 2 ) Color additive mixtures for drug use made with chromium hydroxide green may contain only those diluents listed in this subpart as safe and suitable for use in color additive mixtures for coloring drugs.
( b ) *Specifications.* Chromium hydroxide green shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice: Water soluble matter, not more than 2.5%. Chromium in 2% NaOH extract, not more than 0.1% as Cr2O3 (based on sample weight). Boron (as B2O3), not more than 8 percent. Total volatile matter at 1000 °C, not more than 20%. Cr2O3 not less than 75%. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million.
( c ) *Uses and restrictions.* Chromium hydroxide green may be safely used in amounts consistent with good manufacturing practice to color externally applied drugs, including those for use in the area of the eye.
( d ) *Labeling requirements.* The label of the color additive and of any mixtures prepared therefrom lintended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health, and therefore batches thereof are exempt from the certification requirements of section 721(c) of the act.
[42 FR 36451, July 15, 1977, as amended at 42 FR 59852, Nov. 22, 1977]
Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
Pursuant to 18 U.S.C. Section 1350, as adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

The undersigned, Kevin S. Herrmann, Chief Financial Officer of Ballantyne Strong, Inc. (the "Company"), has executed this
certification in connection with the filing with the Securities and Exchange Commission of the Company's Annual Report on Form 10-K for the year ended December 31, 2010 (the
"Report").

The
undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to his knowledge
that:



IN
WITNESS WHEREOF, the undersigned has executed this certification as of the 16th day of March, 2011.

/s/ KEVIN S. HERRMANN Kevin S. Herrmann
Chief Financial Officer


A
signed original of this written statement required by Section 906 has been provided to Ballantyne Strong, Inc. and will be retained by Ballantyne Strong, Inc. and
furnished to the Securities and Exchange Commission or its staff upon request.

---



QuickLinks
#### § 801.125 Medical devices for use in teaching, law enforcement, research, and analysis.

A device subject to § 801.109 shall be exempt from section 502(f)(1) of this act if shipped or sold to, or in the possession of, persons regularly and lawfully engaged in instruction in pharmacy, chemistry, or medicine not involving clinical use, or engaged in law enforcement, or in research not involving clinical use, or in chemical analysis, or physical testing, and is to be used only for such instruction, law enforcement, research, analysis, or testing.
<PAGE>
 
                                                                      Exhibit 21

                        SUBSIDIARIES OF THE REGISTRANT

SDW Holdings Corporation ("Holdings") was incorporated under the laws of the
State of Delaware and owns or controls the following corporation by means of
owning the indicated percent of its voting securities:


      Percent
Voting Securities                                         State or Province
Owned by Holdings              Subsidiary                 of Incorporation
-----------------              ----------                 -----------------

      100%                 S.D. Warren Company               Pennsylvania


In addition, S.D. Warren Company owns or controls the following corporations by 
means of owning the indicated percents of their voting securities:

                     
      Percent        
 Voting Securities       
     Owned by                                               State or Province
 S.D. Warren Company              Subsidiary                of Incorporation
 -------------------              ----------                -----------------
      100%                       Skylark, Inc.                   Maine
      100%                    Presumpscott Water                 Maine
                                 Power Company
      100%                  S.D. Warren Finance Co.             Delaware
**Exhibit32.2**

 

**CERTIFICATIONOF PERIODIC REPORT**

 

I, Cameron B. Waite, Executive Vice President and Chief FinancialOfficer of Penn Treaty American Corporation, certify, pursuant to Section 906of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

 

(1) the Quarterly Report on Form 10-Q of the Company for the quarterlyperiod ended June 30, 2003 (the “Report’’) fully complies with the requirementsof Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78mor 78o(d)); and

 

(2) the information contained in the Report fairly presents, in allmaterial respects, the financial condition and results of operations of theCompany.

 
| Date:   August 11, 2003 | /s/ Cameron B. Waite                         |   |
|------------------------------|----------------------------------------------|--------|
|                         |                                         |
|                         | Cameron B. Waite                             |
|                         | Exec. Vice President Chief Financial Officer |

 

1

----